RLYB
Rallybio Corp

623
Mkt Cap
$30.53M
Volume
415,099.00
52W High
$1.20
52W Low
$0.2201
PE Ratio
-2.41
RLYB Fundamentals
Price
$0.77
Prev Close
$0.7227
Open
$0.725
50D MA
$0.6172
Beta
1.40
Avg. Volume
212,411.89
EPS (Annual)
-$1.33
P/B
0.51
Rev/Employee
$25,440.00
Loading...
Loading...
News
all
press releases
Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported...
Business Wire·1mo ago
News Placeholder
More News
News Placeholder
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program
Recursion Pharmaceuticals stock jumps after securing full rights to REV102, aiming to fast-track the first oral therapy for hypophosphatasia.
Zacks·5mo ago
News Placeholder
Rallybio to Present at the TD Cowen 45th Annual Health Care Conference
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced...
Business Wire·10mo ago
News Placeholder
Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced...
Business Wire·10mo ago
News Placeholder
Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today...
Business Wire·11mo ago

Latest RLYB News

View

Advertisement|Remove ads.

Advertisement|Remove ads.